UNION CITY, Calif., Dec. 24, 2009 –(HSMN NewsFeed) - Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR ) today announced the U.S. Food & Drug Administration (FDA) now considers that Questcor has provided a complete response to all prior action letters for its s…
Biopharmaceuticals, FDA
Questcor Pharmaceuticals, Acthar, corticotropin

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “FDA Accepts for Review Questcor’s Filing of Its Supplemental New Drug Application for H.P. Acthar(R) Gel for Treatment of Infantile Spasms”
Leave a Comment